Frequently amplified STAT3/5 oncogenes and related kinase action relevant for T‐cell survival were identified as vulnerable nodes for targeting, thereby improving the prospects of a translatable targeted drug for L‐CTCL. The gene discussed is STAT3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.